Adriamycin – efficacy and possible adverse effects
DOI:
https://doi.org/10.1515/cpp-2016-0006Keywords:
adriamycin, cardiotoxicity, hepatotoxicityAbstract
Adriamycin (doxorubicin) is a chemical substance in the anthracycline class with a wide range of applications in oncology and hematology. The mechanism of action of Adriamycin is related to formation of irregular bonds between nucleobases of DNA and inhibition of key enzymes of DNA synthesis - topoisomerase I and II as well as to formation of free radicals damaging DNA.
A major limitation in the drug use is associated with its adverse effects such as cardiotoxicity and hepatotoxicity.
The mechanism of myocardial injury by Adriamycin is linked to an increase in oxidative stress associated with impaired mitochondrial function and structure.
Cardiotoxicity of anthracyclines is classified as: acute, chronic or late (delayed).
Hepatotoxicity of Adriamycin as a damage of the liver is associated with a dysfunction of this organ. Adriamycin studies have shown increased level of transaminase present in 40% of patients treated with Adriamycin. The state was transient and asymptomatic, returning to the initial level even when treatment continued.
Knowledge of cancer diseases contributed to a successive creation of two improved forms of Adriamycin (doxorubicin) – non-pegylated and pegylated formulas of the drug.
The mechanism of anticancer effects of liposomal Adriamycin is similar to the mechanism of conventional Adriamycin, but placement of the molecules of active substance in liposomes has significant influence on the distribution of the drug.
In order to increase the distribution of the drug, a special form of liposomal Adriamycin has been created by covering the surface of the liposomes with a hydrophilic polymer - (MPEG). This process, known as pegylation, decreases the interactions between the lipid bilayer membrane and the plasma components. Pegylated form of the drug is associated with a higher incidence of acute complications
.
References
1. Wallace K.B.: Doxorubicin-induced cardiac mitochondriopathy. Pharmacology & Toxicology 2003; 93:105-115.
2. Denisso T., Kowalski D.M.: Przegląd leków stosowanych w onkologii. W. Krzakowski M. (ed.) Onkologia Kliniczna. Bogris Wy-dawnictwo Medyczne, Warszawa 2006; 235-244.
3. Gniazdowski M., Szmigiero L.: Molekularne mechanizmy oddziaływania związków przeciwnowotworowych na DNA. Na Pograni-czu Chemii i Biologii, 2003; 7: 45-73.
4. Kufe D.W., Holland J.F., Frei E.: Cancer Medicine 6., BC Decker, Hamilton 2003.
5. Jarząbek M., Jargiełło T., Janczarek M., Pyra K., Wolski A., Budzyń-ska A., Szczerbo-Trojanowska M.: Leczenie guzów przerzutowych w wątrobie za pomocą wewnątrznaczyniowej chemoembolizacji z użyciem mikrocząstek nasączonych cytostatykiem (DEM-TACE).Wydawnictwo Borgis - Postępy Nauk Medycznych 5/2012;446-450.
6. Polskie Towarzystwo Urologiczne: Zasady postępowania u chorych na raka pęcherza moczowego. Warszawa 2002.
7. Milczek T., Emerich J., Klasa-Mazurkiewicz D.: Chemioterapia dootrzewnowa w leczeniu chorych na raka jajnika. Curr. Gynecol. Oncol. 2009; 7 (4): 270-281.
8. Wcisło G., Korniluk J., Szarlej-Wcisło K., Pawlak W.Z., Nurzyński P., Duchnowska R.: Leczenie chorób nowotworowych czynnikiem martwicy nowotworów – alfa (TNF-alfa). Współczesna Onkologia, 2002; 4: 222–227.
9. Gabizon et al. Pharmacokinetics of Pegylated Liposomal Doxorubicin Review of Animal and Human Studies. Clin Pharmacokinet 2003; 42 (5): 419-436.
10. National Institute for Health and Clinical Excellence; TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydro-chloride and topotecan (review): Guidance; 25 May 2005.
11. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
12. Gordon A.N., Tonda M., Sun S., Rackoff W.: Long-term survival advantage for women with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of re-current and refractory epithelial ovarian cancer. Gynecol Oncol. 2004; 95:1-8.
13. Podlewski J.K., Chwalibogowska-Podlewska A.: Leki współczesnej terapii. Medical Tribune Polska, Warszawa 2009; 270-271; 288-289.
14. Dwyer Schull P. (ed.). The oncology drug & regiments. New York. Elsevier Oncology 2006; 128-131; 139-143.
15. Wilkers G.M., Barton-Burke M.: Oncology nursing drug handbook 2010. Jones and Bartlett Publishers. Sadbury 2010; 151-154; 163-168.
16. Deptała A., Omyła-Staszewska J., Staszewska-Skurczyńska M.: Kardiotoksyczność antracyklin i kardioprotekcja. Fakty i mity. Wsp. Onkol. 2004; 8: 107-111.
17. Szmit S., Grabowski M.: Powikłania kardiologiczne leczenia raka piersi. Terapia 2008; 16: 46-55.
18. Szmit S., Główczyńska R., Szczylik C., Opolski G.: Niewydolność serca po chemioterapii. Terapia 2007; 15: 77-87.
19. Wilkers G.M., Barton-Burke M.: Oncology nursing drug handbook 2010. Jones and Bartlett Publishers. Sadbury 2010; 151-154; 163-168.
20. Dwyer Schull P. (ed.). The oncology drug & regiments. New York. Elsevier Oncology 2006; 128-131; 139-143.
21. Navarro V.J, Senior J.R.: Drug-related hepatotoxicity. N Engl J Med. 2006; 354: 731-9.
22. King P.D., Perry M.C.: Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162-76.
23. Gonzalez F.J., Turkey R.H.: Drug metabolism. In: Brunton L.L., Lazo J.S., Parker K.L., editors. Goodman & Gilmans the pharmaco-logical basis of therapeutics. Eleventh ed. New York, McGraw-Hill: Medical Publishing Division. 2006; 71-91.
24. Gabizon et al.: Pharmacokinetics of Pegylated Liposomal Doxorubicin Review of Animal and Human Studies. Clin Pharmacokinet 2003; 42 (5): 419-436.
25. Gunawan B.K., Kaplowitz N.: Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004; 36: 301-12.
26. Liu Z.X., Kaplowitz N.: Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-74.
27. Gunawan B.K., Kaplowitz N.: Mechanisms of drug-induced liver disease. Clin Liver Dis 2007; 11: 459-75.
28. Hartleb M.: Polekowe uszkodzenia wątroby. Terapia 2008; 16: 67-74.
29. Ma B., Yeo W., Hui P., Ho W.M., Johnson P.J.: Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer - a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 2002; 62: 185-189.
30. Chalasani N., Fontana R.J., Bonkovsky H.L., Watkins P.B., Davern T., Serrano J., Yang H., Rochon J.; Drug Induced Liver Injury Net-work (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.
31. Reuben A., Koch D.G., Lee W.M.; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-2076.
32. Pieńkowski T. Rak piersi. W: Krzakowski M. (ed.) Onkologia kliniczna. Bogris Wydawnictwo Medyczne, Warszawa 2006; 1014-1056.
33. Waterhouse D.N., Tardi P.G., Mayer L.D. et al.: A comparison of liposomal formulation of doxorubicin with drug administered in free for: changing toxicity profiles. Drug Saf. 2001; 24:903-920.
34. Gabizon A., Catane R., Uziely B. et al.: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated in liposomes. Cancer Res. 1994; 54: 987–992.
35. Rahman A., White G., More N. et al.: Pharmacological, toxicological and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. Cancer Res. 1985; 45: 796–803.
36. Cowens J.W., Creaven P.J., Greco W.R. et al.: Initial clinical (phase I) trial of TLC D–99 (doxorubicin encapsulated in liposomes). Cancer Res. 1993; 53: 2796–802.
37. Safra T., Muggia F., Jeffers S. et al.: Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. 2000; 11: 1029–1033.
38. O’Brien M.E., Wigler N., Inbar M. et al.: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004; 15: 440–449.
39. Waterhouse D.N., Tardi P.G., Mayer L.D. et al.: A comparison of liposomal formulation of doxorubicin with drug administered in free for: changing toxicity profiles. Drug Saf. 2001; 24: 903–920.
40. Harris L., Batist G., Belt R. et al.: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25–36.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
